Actively Recruiting
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Led by RenJi Hospital · Updated on 2026-05-13
46
Participants Needed
1
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
CONDITIONS
Official Title
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female, aged 18 to 70 years
- Histologically confirmed triple-negative breast cancer (ER <10%, PR <10%, and HER2 negative)
- At least one lesion that can be evaluated
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Metastatic (Stage IV) breast cancer
- Pregnancy or breastfeeding
- Women of childbearing potential who test positive for pregnancy at baseline
- Women of childbearing potential unwilling to use effective contraception during the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here